Announcements
- CytoDyn Announces FDA Has Lifted Clinical Hold
- CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
- CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
- CytoDyn Announces Webcast to Provide Company Update
- CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
- November 2023 Letter to Shareholders
- CytoDyn Announces Company Updates and Investment Community Update Webcast
More ▼
Key statistics
On Friday, Cytodyn Inc (296:MUN) closed at 0.133, 13.68% above the 52 week low of 0.117 set on Apr 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.133 |
---|---|
High | 0.133 |
Low | 0.133 |
Bid | 0.128 |
Offer | 0.18 |
Previous close | 0.133 |
Average volume | 0.00 |
---|---|
Shares outstanding | 993.37m |
Free float | 985.39m |
P/E (TTM) | -- |
Market cap | 146.02m USD |
EPS (TTM) | -0.055 USD |
Data delayed at least 15 minutes, as of May 03 2024 07:05 BST.
More ▼